Cantor Fitzgerald Predicts ACAD FY2026 Earnings

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) - Equities researchers at Cantor Fitzgerald issued their FY2026 earnings estimates for shares of ACADIA Pharmaceuticals in a research report issued on Monday, June 9th. Cantor Fitzgerald analyst J. Kim expects that the biopharmaceutical company will earn $0.85 per share for the year. Cantor Fitzgerald has a "Strong-Buy" rating on the stock. The consensus estimate for ACADIA Pharmaceuticals' current full-year earnings is $0.70 per share.

ACADIA Pharmaceuticals (NASDAQ:ACAD - Get Free Report) last issued its earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.11 earnings per share for the quarter, topping the consensus estimate of $0.10 by $0.01. ACADIA Pharmaceuticals had a return on equity of 25.83% and a net margin of 13.83%. The company had revenue of $244.32 million during the quarter, compared to the consensus estimate of $239.32 million. During the same quarter in the prior year, the business earned $0.10 earnings per share. The company's revenue was up 18.7% compared to the same quarter last year.

Other analysts have also issued research reports about the stock. BMO Capital Markets lifted their price objective on shares of ACADIA Pharmaceuticals from $24.00 to $28.00 and gave the company an "outperform" rating in a research note on Monday, May 19th. UBS Group dropped their price target on shares of ACADIA Pharmaceuticals from $25.00 to $22.00 and set a "buy" rating on the stock in a research note on Monday, April 28th. Needham & Company LLC boosted their price objective on shares of ACADIA Pharmaceuticals from $27.00 to $30.00 and gave the stock a "buy" rating in a report on Monday, May 19th. Deutsche Bank Aktiengesellschaft upgraded ACADIA Pharmaceuticals from a "hold" rating to a "buy" rating and raised their target price for the company from $20.00 to $35.00 in a research note on Wednesday, May 21st. Finally, Bank of America lifted their target price on ACADIA Pharmaceuticals from $18.00 to $23.00 and gave the stock a "hold" rating in a research report on Thursday, June 5th. Six analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, ACADIA Pharmaceuticals currently has an average rating of "Moderate Buy" and a consensus target price of $26.79.

ACADIA Pharmaceuticals Price Performance

ACADIA Pharmaceuticals stock traded down $0.03 during midday trading on Tuesday, hitting $21.71. 1,154,100 shares of the company were exchanged, compared to its average volume of 1,942,028. The company has a market cap of $3.63 billion, a PE ratio of 27.83 and a beta of 0.65. ACADIA Pharmaceuticals has a fifty-two week low of $13.40 and a fifty-two week high of $25.23. The company's fifty day moving average price is $18.02 and its 200-day moving average price is $17.84.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. Exchange Traded Concepts LLC bought a new stake in shares of ACADIA Pharmaceuticals during the 1st quarter valued at about $29,000. Banque Transatlantique SA acquired a new position in ACADIA Pharmaceuticals in the first quarter valued at approximately $31,000. Picton Mahoney Asset Management acquired a new position in ACADIA Pharmaceuticals in the first quarter valued at approximately $32,000. Federated Hermes Inc. grew its holdings in shares of ACADIA Pharmaceuticals by 231.5% during the first quarter. Federated Hermes Inc. now owns 2,317 shares of the biopharmaceutical company's stock valued at $38,000 after purchasing an additional 1,618 shares during the last quarter. Finally, Virtus Fund Advisers LLC acquired a new stake in shares of ACADIA Pharmaceuticals during the 4th quarter worth approximately $39,000. 96.71% of the stock is currently owned by institutional investors.

Insider Transactions at ACADIA Pharmaceuticals

In other ACADIA Pharmaceuticals news, insider James Kihara sold 4,000 shares of ACADIA Pharmaceuticals stock in a transaction on Friday, May 16th. The shares were sold at an average price of $22.50, for a total value of $90,000.00. Following the completion of the transaction, the insider now owns 20,395 shares of the company's stock, valued at $458,887.50. The trade was a 16.40% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, EVP Mark C. Schneyer sold 3,171 shares of the business's stock in a transaction on Wednesday, March 26th. The shares were sold at an average price of $17.05, for a total transaction of $54,065.55. Following the sale, the executive vice president now owns 56,889 shares of the company's stock, valued at approximately $969,957.45. The trade was a 5.28% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 33,273 shares of company stock valued at $653,182. Insiders own 26.50% of the company's stock.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.